The discovery of soluble tau aggregates and their involvement in the pathogenesis of AD triggered the development of therapeutics aimed to halt tau aggregation [109–113] or induce tau clearance by immunotherapy [114]. The gene discussed is MAPT; the disease is Alzheimer disease.